4/A: Gyre Therapeutics President Ma Songjiang Corrects Transaction Date in Amended SEC Filing
SEC Filing
Ma Songjiang, President of Gyre Therapeutics, files an amended SEC Form 4 to correct the transaction date of a common stock disposal.
Summary
- This is an amended SEC Form 4 filing by Songjiang Ma, President of Gyre Therapeutics, Inc.
- The amendment corrects the transaction date of a disposal of common stock.
- The original filing incorrectly reported the transaction date as January 3, 2024, but the correct date is January 3, 2025.
- On January 3, 2025, Ma Songjiang disposed of 833 shares of common stock at a price of $11.85 per share.
- Following the transaction, Ma Songjiang beneficially owns 2,918,467 shares indirectly through a spouse.
Sentiment
Score: 5
Explanation: The document is a routine correction of a previously filed form, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Earliest transaction date |
| 01/03/2025 | Corrected transaction date for stock disposal |
| 01/06/2025 | Date of original Form 4 filing |
| 01/10/2025 | Date of amended filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.